← Leaderboards
Channing Paller
Johns Hopkins University
$546,360
Attributed
$546,360
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $177.1K · FY2016–20$200K$150K$100K$50K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$546,360 · 2
By mechanism
K23$531,360 · 1
R13$15,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Peter A Merkel$19,482,229
- Hyder A Jinnah$25,307,523
- Jerry A Krishnan$9,952,509
- Ie-Ming Shih$14,895,140
- Jun Luo$3,173,526
Others in their field
Top investigators on “Comprehensive Cancer Center”
- David Heimbrook · Leidos Biomedical Research, Inc.$128,867,561
- Michael Leo Leblanc · Fred Hutchinson Cancer Research Center$61,076,296
- William J. Blot · Vanderbilt University$60,943,055
- Deborah W Bruner · American College Of Radiology$56,219,531
- Larry Arthur$50,463,849
- Walter John Curran · Thomas Jefferson University$49,939,017
Research focus
Comprehensive Cancer CenterClinical TrialsTrainingMemberCancer PatientOncologyLengthProgramsClinical ResearchAbirateroneCell CountCell PhysiologyBaseAffectChemotherapyAndrogen ReceptorBiomarker PanelAdvisory CommitteesCastrationBiometryBiopsyBloodBiomarker DevelopmentBiology
Grant awards (4)
The Society for Integrative Oncology (SIO) 17th International Conference, "The Science of Living Well With Cancer"$15,000
R13 · FY2020 · CA · contact PI
Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide$177,120
K23 · FY2018 · CA · contact PI
Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide$177,120
K23 · FY2017 · CA · contact PI
Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamide$177,120
K23 · FY2016 · CA · contact PI